North East and North Cumbria
ICS Formulary
ICS Formulary
6 Endocrine system
06-01-06 Blood glucose monitoring
SSC2713 - NHS England: Funding approval for use of continuous glucose monitors in the Congenital Hyperinsulism Service (Children) - Please note that this is for information only as there are no providers within the North East & Cumbria Hub area that are a designated centre commissioned to provide this service.
| Dexcom One® |
|
Formulary
|
|
 NTAG Continuous Glucose Monitoring (CGM) System Position Statement (May 2024) |
|
| Dexcom ONE+® |
|
Formulary
|
|
|
NTAG Continuous Glucose Monitoring (CGM) System Position Statement (May 2024) |
|
|
| Freestyle Libre 2 Plus® |
|
Formulary
|
|
|
NTAG Continuous Glucose Monitoring (CGM) System Position Statement (May 2024) |
|
|
| i-Port Advance® |
|
Formulary
|
|
|
NTAG i-Port Advance® Position Statement |
|
| Freestyle Libre 3 plus® |
|
Formulary
|
|
|
NTAG Continuous Glucose Monitoring (CGM) System Position Statement (May 2024) |
|
|
| Freestyle Libre 3® |
|
Formulary
|
|
|
NTAG Continuous Glucose Monitoring (CGM) System Position Statement (May 2024) |
|
|
Links
MHRA Drug Safety Update (October 2024): Insulin pumps and continuous glucose monitoring (CGM) equipment: guidance for users on reporting suspected adverse incidents and safety concerns to the MHRA’s Yellow Card scheme- NENC Guidelines: Self-Monitoring of Blood Glucose and Ketones in Diabetes
- NHSE Commissioning recommendations following the national assessment of blood glucose and ketone meters, testing strips and lancets
- NICE NG 28: Type 2 diabetes in adults: management
- NICE NG17: Type 1 diabetes in adults: diagnosis and management
- NICE NG18: Diabetes (type 1 and type 2) in children and young people: diagnosis and management
- NICE NG19: Diabetic foot problems: prevention and management
- NICE NG3: Diabetes in pregnancy: management from preconception to the postnatal period
- North East and North Cumbria ICB - Guidelines: Self-Monitoring of Blood Glucose and Ketones in Diabetes
- North East and North Cumbria ICS - Medication Management of Type 2 Diabetes in Adults Guidelines
- NTAG Continuous Glucose Monitoring (CGM) System Position Statement (May 2024)
- NTAG Continuous Glucose Monitoring (CGM) System Position Statement (May 2024)
- NTAG Continuous Glucose Monitoring (CGM) System Position Statement (May 2024)
- NTAG Continuous Glucose Monitoring (CGM) System Position Statement (May 2024)
- NTAG Continuous Glucose Monitoring (CGM) System Position Statement (May 2024)
- NTAG Continuous Glucose Monitoring (CGM) System Position Statement (May 2024)
- NTAG Continuous Glucose Monitoring (CGM) System Position Statement (May 2024)
- NTAG Endocrine System Recommendations
- NTAG i-Port Advance® Position Statement